Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.201
-0.023 (-10.07%)
Apr 29, 2026, 1:11 PM EDT - Market open
Calidi Biotherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Net Income | -19.91 | -22.14 | -29.22 | -25.43 | -10.93 | Upgrade
|
| Depreciation & Amortization | 1.65 | 1.54 | 1.26 | 0.26 | 0.16 | Upgrade
|
| Other Amortization | - | 0.05 | 0.43 | 0.12 | 0.56 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.24 | - | 0.01 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | 0.17 | Upgrade
|
| Stock-Based Compensation | 2.11 | 2.96 | 4.81 | 4.52 | 1.33 | Upgrade
|
| Other Operating Activities | -0.16 | -0.39 | 1.97 | 3.74 | -0.15 | Upgrade
|
| Change in Accounts Payable | -1.33 | -0.63 | -6.17 | 1.62 | -0.24 | Upgrade
|
| Change in Other Net Operating Assets | -3.42 | -1.07 | -0.07 | 1.95 | 1.34 | Upgrade
|
| Operating Cash Flow | -21.29 | -19.69 | -26.98 | -13.21 | -7.77 | Upgrade
|
| Capital Expenditures | -0.12 | -0.02 | -0.59 | -0.43 | -0.21 | Upgrade
|
| Cash Acquisitions | - | - | 0.01 | - | - | Upgrade
|
| Divestitures | -0.05 | - | - | - | - | Upgrade
|
| Other Investing Activities | - | - | 0.1 | -0.07 | -0.01 | Upgrade
|
| Investing Cash Flow | -0.17 | -0.02 | -0.48 | -0.49 | -0.22 | Upgrade
|
| Short-Term Debt Issued | - | 0.2 | 3.25 | 1.5 | 1.5 | Upgrade
|
| Long-Term Debt Issued | - | 3.6 | - | - | 0.38 | Upgrade
|
| Total Debt Issued | - | 3.8 | 3.25 | 1.5 | 1.88 | Upgrade
|
| Short-Term Debt Repaid | -0.4 | -0.3 | -1.3 | -0.04 | -0.1 | Upgrade
|
| Long-Term Debt Repaid | -2.09 | -1.58 | -1.05 | -0.08 | -0.03 | Upgrade
|
| Total Debt Repaid | -2.49 | -1.88 | -2.35 | -0.12 | -0.13 | Upgrade
|
| Net Debt Issued (Repaid) | -2.49 | 1.92 | 0.9 | 1.38 | 1.75 | Upgrade
|
| Issuance of Common Stock | 16.66 | 22.87 | 0.28 | 0.11 | 0.14 | Upgrade
|
| Other Financing Activities | 3.29 | 2.58 | 3.37 | 10.59 | 7.93 | Upgrade
|
| Financing Cash Flow | 17.46 | 27.37 | 29.04 | 12.09 | 9.81 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.01 | -0.01 | -0.01 | -0.03 | -0 | Upgrade
|
| Net Cash Flow | -3.99 | 7.64 | 1.58 | -1.65 | 1.82 | Upgrade
|
| Free Cash Flow | -21.41 | -19.71 | -27.57 | -13.64 | -7.98 | Upgrade
|
| Free Cash Flow Margin | - | - | - | -30315.56% | -1777.28% | Upgrade
|
| Free Cash Flow Per Share | -4.98 | -29.55 | -196.22 | -192.49 | -48.49 | Upgrade
|
| Cash Interest Paid | 1.27 | 0.14 | 0.4 | 0.04 | 0.05 | Upgrade
|
| Cash Income Tax Paid | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Levered Free Cash Flow | -11.85 | -11.65 | -43.96 | 6.74 | 12.15 | Upgrade
|
| Unlevered Free Cash Flow | -11.66 | -10.68 | -43.72 | 6.72 | 11.97 | Upgrade
|
| Change in Working Capital | -4.74 | -1.7 | -6.24 | 3.57 | 1.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.